Journey Medical Corporation

DERM Healthcare Drug Manufacturers Specialty & Generic

Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.3%, EPS grew 93.8%, free cash flow fell 84.1% and total debt rose 1.43%, each against the same quarter a year earlier.

4.97 0.16 −3.12%
Market cap
$144.7M
P/E
0.0×
Fwd P/E
91.8×
Dividend yield
—
F-score
4/9
Altman Z
1.09
Beneish M
−0.82
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 5 3
ROE
(47.05%) (44.03%) (36.61%) (23.77%)
ROA
(11.61%) (13.08%) (10.86%) (6.80%)
ROIC
(13.15%) (15.46%) (13.67%) (5.89%)
Return on Tangible Assets
(51.96%) (38.84%) (35.33%) (22.60%)
Average Days of Receivables
110.50 175.74 141.03 194.04
Free Cash Flow per Share
(0.16) (0.51) (0.25) (0.27)
Free Cash Flow
(3.93) (12.44) (6.70) (7.49)
Other line items

Show all line items

Columns are period end dates